Overview
Patient-Centered Approaches to Treatment and Prevention of Clostridioides difficile Infection
CME Webisodes
Click the "View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Listen in as two patients share their experiences with treatment for C. difficile and its recurrence. In this short webisode Dr. Paul Feuerstadt and Dr. Sahil Khanna discuss fresh insights and strategies for selecting treatment of CDI in real-world settings.
This activity is intended for gastroenterologists, infectious disease specialists, primary care physicians, advanced practice providers and other clinicians who care for patients with initial and recurrent Clostridioides difficile infection.
The Centers for Disease Control and Prevention continues to classify C. difficile as an urgent threat given the great burden on patients and the healthcare system. This Gram-positive bacterium causes diarrhea, abdominal bloating, and colitis in addition to significant morbidity and mortality, increased healthcare costs, and hospital readmission rates. In response to accumulating clinical trial evidence and real-world data, guideline recommendations on the selection of antimicrobial therapy have changed. Clinicians may not be familiar with these changes in the selection and application of antimicrobial therapies for treating initial and recurrent CDI.
Upon completion of this activity, participants will be able to:
- Discuss the selection of antimicrobials considerate of their impact on gut microbiota
- Assess available and updated clinical guidelines to ensure evidence-based therapeutic selection for treatment of initial infection and prevention of recurrent CDI
- Describe clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
Supported by an educational grant from Merck & Co., Inc..
Paul Feuerstadt, MD, FACG, AGAF
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Sahil Khanna, MBBS, MS, FACG
Professor of Medicine
Gastroenterology and Hepatology
Mayo Clinic
Rochester, MN
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Paul Feuerstadt, MD, FACG, AGAF
Consulting Agreements: Ferring Pharmaceuticals, Roche Diagnostics, Seres Therapeutics, Takeda Pharmaceuticals
Speakers' Bureau: Merck and Co.
Sahil Khanna, MBBS, MS
Sources of Funding for Grant/Research: Finch Therapeutics, Pfizer, Rebiotx/Ferring, Seres Therapeutics, Vedanta
Consulting Agreements: Immuron, Jetson, Niche, ProBioTech, Shire/Takeda,
Stockholder: Jetson
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational microbiota restoration therapies
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
